<p>Long time friends and industry colleagues, Lisa Chamberlain James with Trilogy and Cheryl Roberts with BioMarin Pharmaceutical sit down to discuss orphan drugs. They go over clinical trial hurdles, key incentives for health authorities, the medical writing process and start with an important question – why are orphan drugs called orphan drugs? Find out on episode 28 of TriloTalk!  </p>

Long time friends and industry colleagues, Lisa Chamberlain James with Trilogy and Cheryl Roberts with BioMarin Pharmaceutical sit down to discuss orphan drugs. They go over clinical trial hurdles, key incentives for health authorities, the medical writing process and start with an important question – why are orphan drugs called orphan drugs? Find out on episode 28 of TriloTalk!

<p>Long time friends and industry colleagues, Lisa Chamberlain James with Trilogy and Cheryl Roberts with BioMarin Pharmaceutical sit down to discuss orphan drugs. They go over clinical trial hurdles, key incentives for health authorities, the medical writing process and start with an important question – why are orphan drugs called orphan drugs? Find out on episode 28 of TriloTalk! &nbsp;</p>

Episode 28: Exploring the Past, Present and Future of Orphan Drugs

Conversations to bring medical writing topics to the forefront and hopefully spark wider conversations in the domain of medical writing. TriloTalk episodes will range from the value of medical writing to apprenticeship. TriloTalk will also cover document-specific topics such as lay summaries and how to tame CTD dossiers.

Share Episode 28: Exploring the Past, Present and Future of Orphan Drugs

Sign up to save your podcasts

Episode 28: Exploring the Past, Present and Future of Orphan Drugs

Episode 28: Exploring the Past, Present and Future of Orphan Drugs